Stay updated with breaking news from Structure Activity Relationships. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
- Publication explores structure-activity relationships of a broad range of 2C-X analogs - - Innovative research led to the discovery of CYB210010, a potent and long-acting serotonin 5-HT2...
Single-target agreement focused on development of novel, small molecule agonists of GPR52 discovered by Sosei Heptares with the potential to simultaneously address positive, negative and cognitive symptoms of schizophreniaSosei Heptares will receive EUR 25 million upfront from Boehringer Ingelheim and is eligible for an option exercise payment of EUR 60 million and further milestone payments totaling up to EUR 670 million plus tiered royalties Ingelheim, Germany, Tokyo, Japan and Cambridge, UK,
Scientific Journal Article follows notable IP updates, including publication of key PCT Patent Application, presentation at International Society for Research into Psychedelics ConferenceVANCOUVER, British Columbia, Feb. 20, 2024 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased that
This quarterly newsletter provides essential updates on litigation, regulatory, legislative, and other notable developments involving chemicals of concern to business.
This quarterly newsletter provides essential updates on litigation, regulatory, legislative, and other notable developments involving chemicals of concern to business.